Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.

[1]  Sejal M. Patel,et al.  R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6 , 2007, Proceedings of the National Academy of Sciences.

[2]  R. O’Keefe,et al.  Bone Morphogenetic Protein 2 Activates Smad6 Gene Transcription through Bone-specific Transcription Factor Runx2* , 2007, Journal of Biological Chemistry.

[3]  B. Alman,et al.  β-Catenin Signaling Pathway Is Crucial for Bone Morphogenetic Protein 2 to Induce New Bone Formation* , 2007, Journal of Biological Chemistry.

[4]  G. Roodman,et al.  Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. , 2006, Blood.

[5]  P. Kostenuik,et al.  Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. , 2006, Bone.

[6]  R. Baron,et al.  Deletion of a Single Allele of the Dkk1 Gene Leads to an Increase in Bone Formation and Bone Mass , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  J. Shaughnessy,et al.  Role of osteoblast suppression in multiple myeloma , 2006, Journal of cellular biochemistry.

[8]  M. Tamura,et al.  Cross-talk between Wnt and Bone Morphogenetic Protein 2 (BMP-2) Signaling in Differentiation Pathway of C2C12 Myoblasts* , 2005, Journal of Biological Chemistry.

[9]  Toshio Matsumoto,et al.  Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. , 2005, Blood.

[10]  M. Karperien,et al.  Downregulation of Wnt Signaling by Increased Expression of Dickkopf‐1 and ‐2 is a Prerequisite for Late‐Stage Osteoblast Differentiation of KS483 Cells , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  J. Shaughnessy,et al.  Wnts induce migration and invasion of myeloma plasma cells. , 2005, Blood.

[12]  S. Aaronson,et al.  Prostate cancer cells promote osteoblastic bone metastases through Wnts. , 2005, Cancer research.

[13]  Caiying Guo,et al.  Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation , 2005, Nature Genetics.

[14]  Bart O. Williams,et al.  Essential Role of β-Catenin in Postnatal Bone Acquisition* , 2005, Journal of Biological Chemistry.

[15]  Hans Clevers,et al.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.

[16]  Su‐Li Cheng,et al.  β‐Catenin and BMP‐2 synergize to promote osteoblast differentiation and new bone formation , 2005, Journal of cellular biochemistry.

[17]  N. Rosenblum,et al.  Smad1, β-catenin and Tcf4 associate in a molecular complex with the Myc promoter in dysplastic renal tissue and cooperate to control Myc transcription , 2004, Development.

[18]  D. Ornitz,et al.  Sequential roles of Hedgehog and Wnt signaling in osteoblast development , 2004, Development.

[19]  Matthias B. Wahl,et al.  Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis , 2004, Development.

[20]  J. Westendorf,et al.  Wnt signaling in osteoblasts and bone diseases. , 2004, Gene.

[21]  Xi He,et al.  LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: Arrows point the way , 2004, Development.

[22]  Toshio Matsumoto,et al.  Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1α and MIP‐1β correlates with lytic bone lesions in patients with multiple myeloma , 2004, British journal of haematology.

[23]  R. Nusse,et al.  Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.

[24]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[25]  Roland Baron,et al.  BMP‐2 Controls Alkaline Phosphatase Expression and Osteoblast Mineralization by a Wnt Autocrine Loop , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  Yoshiaki Kawano,et al.  Secreted antagonists of the Wnt signalling pathway , 2003, Journal of Cell Science.

[27]  L. Hofbauer,et al.  RANK ligand and osteoprotegerin in myeloma bone disease. , 2003, Blood.

[28]  J. Rubin,et al.  Wnt signaling in B-cell neoplasia , 2003, Oncogene.

[29]  Su-Jae Lee,et al.  Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. , 2002, Blood.

[30]  Jonathan R Pollack,et al.  A transcriptional response to Wnt protein in human embryonic carcinoma cells , 2002, BMC Developmental Biology.

[31]  Christof Niehrs,et al.  Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling , 2002, Nature.

[32]  S. Rudikoff,et al.  Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. , 2002, Blood.

[33]  Hans Clevers,et al.  Wnt Signaling Controls the Phosphorylation Status of β-Catenin* , 2002, The Journal of Biological Chemistry.

[34]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[35]  Ivan Lobov,et al.  Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.

[36]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[37]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[38]  J. Michaeli,et al.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Heldin,et al.  Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads , 2001, The EMBO journal.

[40]  Yan Li,et al.  LDL-receptor-related protein 6 is a receptor for Dickkopf proteins , 2001, Nature.

[41]  J. Berenson,et al.  Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. , 2001, Seminars in oncology.

[42]  S. Aaronson,et al.  Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts , 1998, Oncogene.

[43]  F. Lecanda,et al.  Human Osteoblasts Express a Repertoire of Cadherins, Which Are Critical for BMP‐2–Induced Osteogenic Differentiation , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  T. Yoneda,et al.  Smad5 and DPC4 Are Key Molecules in Mediating BMP-2-induced Osteoblastic Differentiation of the Pluripotent Mesenchymal Precursor Cell Line C2C12* , 1998, The Journal of Biological Chemistry.

[45]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[46]  P. Edwards,et al.  Alterations of the growth characteristics of the fibroblast cell line C3H 10T1/2 by members of the Wnt gene family. , 1994, Oncogene.

[47]  J. Kanis,et al.  Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption , 1992, European journal of haematology.

[48]  R. Bataille,et al.  Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Benoit Robert,et al.  SMAD 8 binding to mice Msx1 basal promoter is required for transcriptional activation. , 2006, The Biochemical journal.

[50]  R. Nusse,et al.  Wnt signaling in disease and in development , 2005, Cell Research.

[51]  S. Rudikoff,et al.  Wnt signaling in B and T lymphocytes. , 2004, Frontiers in bioscience : a journal and virtual library.

[52]  Mark L. Johnson,et al.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.

[53]  A. Economides,et al.  0163-769X/03/$20.00/0 Endocrine Reviews 24(2):218–235 Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/er.2002-0023 Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton , 2022 .